Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 303 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Menopause Symptoms Clear all
Completed Phase 3 Interventional Results available

Flaxseed in Treating Postmenopausal Women With Hot Flashes Who Have a History of Breast Cancer or Other Cancer or Who Do Not Wish to Take Estrogen Therapy

NCT00956813
View directory record Official record
Conditions
Breast Cancer, Hot Flashes, Menopausal Symptoms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
flaxseed, placebo
Dietary Supplement · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
107
States / cities
Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 20, 2026, 8:45 AM EDT
Terminated Not applicable Interventional

Vesair Clinical Trial

NCT04026347
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
Vesair Balloon, Sham balloon placement
Device · Other
Lead sponsor
Solace Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
25
States / cities
Phoenix, Arizona • San Diego, California • Temecula, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

NCT03359473
View directory record Official record
Conditions
Cachexia
Interventions
GSK2881078, Matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Torrance, California • Jacksonville, Florida • High Point, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen and Serotonin on Changing Brain Chemistry

NCT01208324
View directory record Official record
Conditions
Menopause
Interventions
estrogen patch, Amino acids, Placebo Patch, Placebo pills
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
48 Years to 60 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2021 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Early Phase 1 Interventional

Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness

NCT02029053
View directory record Official record
Conditions
Menopausal and Perimenopausal Disorder, Unspecified, Atrophic Vaginitis
Interventions
Vaginal Lubrication Ring for Vaginal Dryness
Device
Lead sponsor
J3 Bioscience, Inc.
Industry
Eligibility
35 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 2 Interventional Results available

Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen

NCT00764322
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms
Interventions
tamoxifen citrate, gene expression analysis, pharmacogenomic studies, questionnaire administration, quality-of-life assessment
Drug · Genetic · Other + 1 more
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years to 120 Years · Female only
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
7
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 20, 2026, 8:45 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia

NCT02483195
View directory record Official record
Conditions
Female Androgenetic Alopecia
Interventions
5% Minoxidil, 200mg Spironolactone, 5mg Finasteride, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
60 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pilot Study of Bazedoxifene Plus Conjugated Estrogen on Imaging and Blood Biomarkers

NCT04821375
View directory record Official record
Conditions
Increased Risk for Development of Breast Cancer
Interventions
bazedoxifene plus conjugated estrogens
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 20, 2026, 8:45 AM EDT
Not listed Phase 1 Interventional

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

NCT04660929
View directory record Official record
Conditions
HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer, Bladder Cancer, Breast Cancer, Breast Neoplasm, Carcinoma, Ductal, Carcinoma, Hepatocellular, Cancer, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Carcinoma, Small Cell, Carcinoma, Squamous, Carcinoma, Transitional Cell, Colorectal Cancer, Esophagogastric Junction Neoplasms, Inflammatory Breast Cancer, Stomach Neoplasms, Malignant Neoplasms, Ovarian Neoplasms, Pancreatic Cancer, HER2-positive Solid Tumors, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER-2 Protein Overexpression, HER-2 Gene Amplification, Prostate Cancer, Head and Neck Cancer, Endometrial Cancer, Lung Cancer, Small Cell
Interventions
CT-0508, Pembrolizumab
Biological
Lead sponsor
Carisma Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Womens Study to Alleviate Vasomotor Symptoms

NCT04587154
View directory record Official record
Conditions
Hot Flashes
Interventions
low-fat vegan diet with 1/2 cup soybeans daily
Other
Lead sponsor
Physicians Committee for Responsible Medicine
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Sukshma Vyayama Yoga on Aromatase Inhibitor-Induced Arthralgia in Breast Cancer Survivors

NCT04042870
View directory record Official record
Conditions
Breast Cancer
Interventions
Joint Loosening Yoga
Behavioral
Lead sponsor
AshtaYoga, LLC
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

NCT05099159
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 20, 2026, 8:45 AM EDT
Active, not recruiting No phase listed Observational

Endometrial Cancer Vaginal Fluid Specimen Collection Study

NCT07544680
View directory record Official record
Conditions
Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions
Not listed
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 20, 2026, 8:45 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia

NCT06644573
View directory record Official record
Conditions
Chronic Insomnia, Sleep Deprivation, REM Behavior Disorder, REM Sleep Behavior Disorder, REM Sleep Measurement, Insomnia, Insomnia Related to Specified Disorder, Insomnia Due to Other Mental Disorder, Insomnia Comorbid to Psychiatric Disorder, Insomnia Due to Anxiety and Fear, Insomnia Related to Another Mental Condition, Insomnia Disorders, Idiopathic Hypersomnia, Sleep Disorders, Circadian Rhythm, Post Trauma Nightmares, PTSD - Post Traumatic Stress Disorder, Sleep Quality, Anesthesia, Anxiety, Depression, Mental Health, Alzheimer Disease or Associated Disorder, Parkinsons, Circadian Rhythm, Circadian Dysregulation, PTSD, Post-Traumatic, Post-Traumatic Stress Disorder Complex, Military Combat Stress Reaction, Sleep, Military Activity, Veterans, Shift Work Sleep Disorder, Menopause Related Conditions, Pain, Cancer Pain, Athletes
Interventions
PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca, Continuous EEG Monitoring
Procedure · Drug · Device
Lead sponsor
Nyree Penn
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Effects of Soy Isoflavones on Menopausal Hot Flashes

NCT00179556
View directory record Official record
Conditions
Menopausal Symptoms
Interventions
Isoflavone supplement
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
38 Years to 65 Years · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

NCT01901679
View directory record Official record
Conditions
Obesity
Interventions
Celebrex
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 20, 2026, 8:45 AM EDT
Terminated Not applicable Interventional

The Effects of Lateralized Thermal Sleepwear on Sleep, Skin Temperature and Skin Moisture in Menopausal Women

NCT03037554
View directory record Official record
Conditions
Menopause Related Conditions
Interventions
Sleepwear with Lateralized Thermal Characteristics, Sham-Lateralized Sleepwear
Device
Lead sponsor
St. Peter's Hospital, Albany, NY
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 20, 2026, 8:45 AM EDT
Enrolling by invitation Not applicable Interventional

A Randomized Controlled Trial of Menopausal Tool/App for Women

NCT06919887
View directory record Official record
Conditions
Menopausal Symptoms, Menopause Symptom Management
Interventions
EMMII, Comparison Group
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
24 Years to 80 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 8:45 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Understanding the Roles of Hormones in Adipocyte Remodeling Following Menopause

NCT03856268
View directory record Official record
Conditions
Menopause Surgical, Estrogen Deficiency, Adiposity, Follicle-Stimulating Hormone Deficiency, Hormone Deficiency
Interventions
'Surgical Menopause' Group, 'Drug-Induced Menopause' Group
Procedure · Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional

Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer

NCT00031811
View directory record Official record
Conditions
Breast Cancer, Menopausal Symptoms, Osteoporosis
Interventions
raloxifene, quality-of-life assessment
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 28, 2012 · Synced Oct 20, 2026, 8:45 AM EDT
Completed No phase listed Observational

Steroid Therapy in Autoimmune Premature Ovarian Failure

NCT00001306
View directory record Official record
Conditions
Autoimmune Disease, Infertility, Premature Ovarian Failure
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 39 Years · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 8:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Examine the Effects of a Daily Supplement on Common Symptoms of Perimenopause and Menopause

NCT06018740
View directory record Official record
Conditions
Menopause, Perimenopause
Interventions
Daily Balance Gummy
Dietary Supplement
Lead sponsor
Hologram Sciences
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 20, 2026, 8:45 AM EDT
Recruiting Not applicable Interventional

Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause

NCT07688720
View directory record Official record
Conditions
Perimenopause, PMDD
Interventions
transcutaneous auricular neurostimulation (tAN)
Device
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 8:45 AM EDT